Integrum is granted patent approval for its OPRA[TM] Implant System from the US Patent and Trade Organization
Mölndal, Sweden, October 11[th], 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has received a patent approval in the US describing components and design features of the OPRA[TM] Implant System, including elements that were implemented in 2017 and later were granted a PMA approval in late 2020. The patent period extends until 2044.Integrum develops the OPRA[TM ]Implant System, a revolutionary implant technology based on the company’s deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality